PL418704A1 - Concentration of zinc and copper in blood as a risk factor for cancers - Google Patents

Concentration of zinc and copper in blood as a risk factor for cancers

Info

Publication number
PL418704A1
PL418704A1 PL418704A PL41870416A PL418704A1 PL 418704 A1 PL418704 A1 PL 418704A1 PL 418704 A PL418704 A PL 418704A PL 41870416 A PL41870416 A PL 41870416A PL 418704 A1 PL418704 A1 PL 418704A1
Authority
PL
Poland
Prior art keywords
zinc
copper
concentration
cancers
blood
Prior art date
Application number
PL418704A
Other languages
Polish (pl)
Inventor
Jan Lubiński
Anna Jakubowska
Wojciech Marciniak
Magdalena Muszyńska
Katarzyna Kaczmarek
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL418704A priority Critical patent/PL418704A1/en
Publication of PL418704A1 publication Critical patent/PL418704A1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określania ryzyka raka u ludzi, charakteryzujący się tym, że obejmuje korelacje między stężeniem cynku oraz wartością stosunku stężeń miedzi do cynku (Cu/Zn) w surowicy.The subject of the application is a method for determining the risk of cancer in humans, characterized in that it includes correlations between the concentration of zinc and the value of the ratio of copper to zinc (Cu / Zn) in serum.

PL418704A 2016-09-15 2016-09-15 Concentration of zinc and copper in blood as a risk factor for cancers PL418704A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL418704A PL418704A1 (en) 2016-09-15 2016-09-15 Concentration of zinc and copper in blood as a risk factor for cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL418704A PL418704A1 (en) 2016-09-15 2016-09-15 Concentration of zinc and copper in blood as a risk factor for cancers

Publications (1)

Publication Number Publication Date
PL418704A1 true PL418704A1 (en) 2018-03-26

Family

ID=61661140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL418704A PL418704A1 (en) 2016-09-15 2016-09-15 Concentration of zinc and copper in blood as a risk factor for cancers

Country Status (1)

Country Link
PL (1) PL418704A1 (en)

Similar Documents

Publication Publication Date Title
MX2022010224A (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201690617A1 (en) COMBINING ANTI-LAG-3-ANTIBODIES AND ANTI-PD-1-ANTIBODIES FOR THE TREATMENT OF TUMORS
MX2019009812A (en) CHEMERIC PROTEINS BASED ON TIGIT AND LIGHT.
EA201891983A1 (en) COMBINED THERAPY WITH ANTIBODIES TO CD73
IL253871B (en) Multispecific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
MX2016013261A (en) Method for the quantification of parasite eggs in feces.
EA201892802A1 (en) Derivatives of adenosine for use in the treatment of cancer
CL2016000351A1 (en) Method for quantification of actinium-227 in radio-223 compositions.
EA202190633A1 (en) DOSAGE FORMS FOR USE IN PEDIATRICS, METHODS OF OBTAINING AND APPLICATION
SG11202011268VA (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
EA201890739A1 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA
MX2021013461A (en) Method of treating lower tract urothelial cancer.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
PL422787A1 (en) Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
EA201891528A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER
PE20160533A1 (en) MONOCLONAL ANTIBODIES AGAINST ANTITHROMBIN BETA FORMING COMPLEXES WITH HEPARIN
MX2016007148A (en) A-glucan assay methods.
EP3514156A4 (en) 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2h-tetrazolium salt, biological component concentration measurement reagent containing said salt, and biological component concentration measurement method using said salt
NZ714014A (en) Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
PL422750A1 (en) Method for determining the risk of cancers in men, depending on their age and concentration of chosen microelements
EA201891540A1 (en) NANOELECTRODE FOR DETERMINATION OF CU (II) IONS AND METHOD FOR OBTAINING AND APPLICING NANOELECTRODE
DK3638109T3 (en) METHOD FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN WHOLE BLOOD